PMID: 3512428Mar 1, 1986Paper

Captopril modifies the hemodynamic and neuroendocrine responses to sodium nitroprusside in hypertensive patients

Hypertension
W A ClementiT K Keeton

Abstract

To determine if clinically effective doses of the antihypertensive agent captopril affected the neuronal release of norepinephrine or baroreflex sensitivity, changes in plasma norepinephrine concentration and heart rate were related to the changes in mean arterial pressure seen during the intravenous infusion of stepwise incremental doses of sodium nitroprusside before and during captopril treatment in eight hypertensive men with normal or low plasma renin activity. At all times, significant linear correlations were found between the decrease in mean arterial pressure and the dose of sodium nitroprusside, the increase in heart rate and the decrease in mean arterial pressure, and the increase in plasma norepinephrine concentration and the decrease in mean arterial pressure. When the subjects were treated with captopril (25 mg t.i.d.) for 2 to 4 weeks, supine mean arterial pressure decreased from 130 to 114 mm Hg (-12%; p less than 0.05), heart rate did not change, supine and upright plasma renin activity increased, while supine plasma norepinephrine and epinephrine concentration decreased slightly. Therapy with captopril (25 mg t.i.d.) increased baroreflex sensitivity, as assessed by the slope of the regression line relating the...Continue Reading

References

Mar 2, 1972·The New England Journal of Medicine·H R BrunnerF R Bühler
Jan 1, 1967·International Journal of Neuropharmacology·B G Zimmerman, L Whitmore
Dec 1, 1984·Journal of Hypertension·B G ZimmermanP C Wong
Jan 1, 1982·Clinical and Experimental Hypertension. Part A, Theory and Practice·A P NiarchosJ H Laragh
Jan 1, 1984·Journal of Cardiovascular Pharmacology·A M ShepherdT K Keeton
Dec 1, 1980·Clinical Science·S L SwartzR G Dluhy
Apr 21, 1982·The American Journal of Cardiology·G MuiesanA Zanielli
Mar 25, 1983·European Journal of Pharmacology·A De JongeP A Van Zwieten
Oct 1, 1983·Clinical Pharmacology and Therapeutics·M S LinT K Keeton
Nov 1, 1981·Hypertension·M J AntonaccioD Kotler
Apr 21, 1982·The American Journal of Cardiology·G ManciaA Zanchetti
Jan 1, 1983·Hypertension·A M ShepherdT K Keeton
May 1, 1980·Clinical Pharmacology and Therapeutics·K J KripalaniB H Migdalof
Feb 1, 1981·Journal of Clinical Pharmacology·R G Devlin, P M Fleiss
Nov 1, 1981·Clinical Science·G L JenningsP I Korner
Jan 28, 1982·The New England Journal of Medicine·D G VidtF M Fouad

❮ Previous
Next ❯

Citations

Jan 1, 1987·Cardiovascular Drugs and Therapy·I L Natoff
Jan 1, 1988·Clinical and Experimental Hypertension. Part A, Theory and Practice·H MurataniK Fukiyama
Jan 1, 1990·Clinical and Experimental Hypertension. Part A, Theory and Practice·H MurataniK Fukiyama
Dec 1, 1996·Risk Analysis : an Official Publication of the Society for Risk Analysis·J H DriverG K Whitmyre
Dec 25, 2010·Science China. Life Sciences·Xinhua HeMinggang Xu
Apr 1, 1988·British Journal of Clinical Pharmacology·R DonnellyP A Meredith

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.